Philadelphia, PA – October 2025 – 1315 Capital, a healthcare-dedicated growth equity firm focused on commercial-stage companies, has been recognized on Inc.’s 2025 Founder-Friendly Investors list, which honors private equity and venture capital firms that excel in supporting and scaling founder-led businesses.
The recognition underscores 1315 Capital’s reputation as a collaborative, long-term partner to healthcare founders. By combining strategic insight, operational expertise, and capital, 1315 Capital helps founders expand their reach, strengthen leadership teams, and achieve scale, all while maintaining the mission and values that define their companies.
Since its founding, 1315 Capital has invested across four key verticals: Healthcare Services, Pharma/Medtech Products, Pharma/Medtech Outsourcing, and Health & Wellness. Typical equity investments range from $15 million to $50 million, targeting businesses with the potential to reach $50 million to $200 million in revenue. The firm’s flexible investment model, which includes minority growth equity, majority buyouts, and strategic carveouts, enables it to tailor partnerships that best fit each company’s stage and goals.
The recognition affirms 1315 Capital’s role as a trusted partner to founders, helping healthcare companies scale into significant businesses that positively impact patients, physicians, and the broader healthcare system.
View the full list of honorees here.
Inc.’s 2025 Founder-Friendly Investors list recognizes private equity and venture capital firms that support founder-led businesses. Firms are selected through an application process and by Inc.’s editors. 1315 Capital applied for consideration and paid a $1,295 application fee as part of that process. The firm was notified of its inclusion in July 2025, based on portfolio company exits completed since January 1, 2020.
